<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03260023</url>
  </required_header>
  <id_info>
    <org_study_id>TG4001.12</org_study_id>
    <nct_id>NCT03260023</nct_id>
  </id_info>
  <brief_title>Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers</brief_title>
  <official_title>A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Transgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will consist of two parts :&#xD;
&#xD;
      In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 patients at&#xD;
      increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will&#xD;
      be no intra-patient dose escalation.&#xD;
&#xD;
      In the phase II part 1, evaluation of efficacy and further evaluation of safety of the&#xD;
      combination of TG4001 and avelumab will be performed in a single arm of patients with&#xD;
      recurrent or metastatic HPV-16 positive advanced malignancies.&#xD;
&#xD;
      In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will&#xD;
      be performed in a randomized, open-label controlled study comparing TG4001 in combination&#xD;
      with avelumab to avelumab alone in patients with HPV-16 positive advanced malignancies.&#xD;
&#xD;
      In both phases, tumor response will be evaluated on local assessment using RECIST 1.1.&#xD;
&#xD;
      All patients will be followed up until disease progression, death, or unacceptable toxicity,&#xD;
      or study withdrawal for any reason, whichever occurs first.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: To evaluate the safety and tolerability of the combination of TG4001 plus avelumab in patients with recurrent or metastatic HPV-16 positive advanced malignancies</measure>
    <time_frame>Day 28</time_frame>
    <description>Dose limiting toxicities (DLTs) includes the following:&#xD;
Grade ≥ 3 drug related adverse event (AEs). However, fatigue, nausea/vomiting adequately treated with anti-emetics, endocrinopathies adequately controlled with one physiologic hormone replacement, skin toxicity and single laboratory values out of normal range without any clinical correlate, asymptomatic grade ≥3 lipase or amylase elevation, tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor or a transient Grade 3 infusion adverse event are excluded.&#xD;
Liver function test abnormality:&#xD;
AST or ALT &gt; 5 x ULN&#xD;
Total bilirubin &gt; 3 x ULN&#xD;
Concurrent AST or ALT &gt; 3 x ULN and total bilirubin &gt; 2 x ULN&#xD;
Drug related AE requiring treatment interruption for more than 2 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II part 1: Overall Response Rate (ORR) by RECIST 1.1</measure>
    <time_frame>Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years</time_frame>
    <description>Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria over the the total number of evaluable patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II part 2: Progression Free Survival (PFS) by RECISIT 1.1</measure>
    <time_frame>Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years</time_frame>
    <description>Time from the date of randomization to death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by using RECIST 1.1 (phase Ib, phase II part 2)</measure>
    <time_frame>Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years</time_frame>
    <description>Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria over the the total number of evaluable patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) (phase Ib, Phase II part 1)</measure>
    <time_frame>Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years</time_frame>
    <description>Time from the date of first study treatment administration (Phase IB, Phase II Part1) to the date of first documented tumor progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Every 3 months and up to 3 years</time_frame>
    <description>Time from the date of first study treatment administration (Phase Ib, Phase II part 1) or time from the date of randomization (Phase II part 2) to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall Response (DoR)</measure>
    <time_frame>Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years</time_frame>
    <description>Time from first documented response (CR or PR) until documented disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years</time_frame>
    <description>Proportion of patients whose best overall response is either CR, PR, or SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Event reported per CTCAE v4.03</measure>
    <time_frame>up to 90 days after last study treatment administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HPV-Related Carcinoma</condition>
  <condition>HPV-Related Cervical Carcinoma</condition>
  <condition>HPV-Related Anal Squamous Cell Carcinoma</condition>
  <condition>HPV-Related Penile Squamous Cell Carcinoma</condition>
  <condition>HPV-Related Vulvar Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>TG4001/Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applicable for Phase II part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TG4001</intervention_name>
    <description>PhIb: Dose escalation PhII: Established RP2D for TG4001</description>
    <arm_group_label>TG4001/Avelumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Anti PD-L1</description>
    <arm_group_label>Avelumab</arm_group_label>
    <arm_group_label>TG4001/Avelumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male patients, aged at least 18 years (no upper limit of age)&#xD;
&#xD;
          -  ECOG PS 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Patients with histologically or cytologically documented metastatic or&#xD;
             refractory/recurrent HPV-16 + cancer: cervical, vulvar, vaginal, penile and anal.&#xD;
&#xD;
          -  Disease MUST not be amenable to curative surgery resection or curative radiotherapy&#xD;
             with documented disease progression&#xD;
&#xD;
          -  Prior therapy:&#xD;
&#xD;
               -  No more than one prior systemic treatment for recurrent /metastatic disease&#xD;
&#xD;
               -  Prior treatment for recurrent or metastatic disease is not required for:&#xD;
&#xD;
                    -  Patients with recurrence/progression within 6 months after completion of&#xD;
                       prior multimodal therapy for localized or locally advanced disease&#xD;
&#xD;
                    -  Patients who are unsuitable for platinum-based therapy&#xD;
&#xD;
                    -  Patients who refuse chemotherapy or other standard therapies for the&#xD;
                       treatment of metastatic or recurrent disease&#xD;
&#xD;
          -  Limited hepatic disease for patients with liver metastases at baseline&#xD;
&#xD;
          -  Availability of tumor tissue from biopsy&#xD;
&#xD;
          -  At least one measurable lesion by CT scan according to RECIST 1.1.&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal function&#xD;
&#xD;
          -  Negative blood pregnancy test at screening for women of childbearing potential&#xD;
&#xD;
          -  Highly effective contraception for both male and female patients if the risk of&#xD;
             conception exists during the study period and for 3 months after the last study&#xD;
             treatment administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to cancer immunotherapy including cancer vaccines, any antibody/drug&#xD;
             targeting T cell co-regulatory proteins (immune checkpoints)&#xD;
&#xD;
          -  Patients under chronic treatment with systemic corticosteroids or other&#xD;
             immunosuppressive drugs for a period of at least 4 weeks and whose treatment was not&#xD;
             stopped 2 weeks prior to the first study treatment, with the exception of patients&#xD;
             with adrenal insufficiency who may continue corticosteroids at physiological&#xD;
             replacement dose, equivalent to ≤ 10 mg prednisone daily. Steroids with no or minimal&#xD;
             systemic effect (topical, inhalation) are allowed&#xD;
&#xD;
          -  Patients with CNS metastases except those with brain metastases treated locally and&#xD;
             clinically stable during 4 weeks prior to start of study treatment, and those without&#xD;
             ongoing neurological symptoms that are related to the brain localization of the&#xD;
             disease&#xD;
&#xD;
          -  Other active malignancy requiring concurrent systemic intervention&#xD;
&#xD;
          -  Patients with previous malignancies other than the target malignancy to be&#xD;
             investigated in this trial (except non-melanoma skin cancers, and the following in&#xD;
             situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or&#xD;
             breast) are excluded unless a complete remission was achieved at least 2 years prior&#xD;
             to study entry AND no additional therapy is required during the study period&#xD;
&#xD;
          -  Patient with any organ transplantation, including allogeneic stem cell transplantation&#xD;
&#xD;
          -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTC),&#xD;
             any history of anaphylaxis, or uncontrolled asthma&#xD;
&#xD;
          -  Any known allergy or reaction to eggs, gentamycin or attributed to compounds of&#xD;
             similar chemical or biological composition to therapeutic vaccines/immunotherapeutic&#xD;
             products&#xD;
&#xD;
          -  Any known allergy or reaction to any component of anti-PD-L1/PD-1 or its excipients&#xD;
&#xD;
          -  Patients with known history or any evidence of active interstitial lung disease /&#xD;
             pneumonitis&#xD;
&#xD;
          -  Patients with active, known, or suspected auto-immune disease or immunodeficiency,&#xD;
             except type I diabetes mellitus, hypothyroidism only requiring hormone replacement or&#xD;
             skin disorders (such as vitiligo, psoriasis) not requiring systemic treatment&#xD;
&#xD;
          -  Clinically significant (that is, active) cardiovascular disease: cerebral vascular&#xD;
             accident/stroke or myocardial infarction (&lt; 6 months prior to enrollment), unstable&#xD;
             angina pectoris, congestive heart failure (New York Heart Association Classification&#xD;
             Class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication/active&#xD;
             intervention, history of myocarditis&#xD;
&#xD;
          -  History of uncontrolled intercurrent illness including but not limited to:&#xD;
&#xD;
               -  Hypertension uncontrolled by standard therapies (not stabilized to 150/90 mmHg or&#xD;
                  lower)&#xD;
&#xD;
               -  Uncontrolled diabetes (e.g., hemoglobin A1c ≥ 8%)&#xD;
&#xD;
               -  Uncontrolled infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Transgene EU, Clinical Operations Department</last_name>
    <phone>+ 33 (0) 3 88 27 91 00</phone>
    <email>clinical.trials@transgene.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>I.C.O. Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint André - CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar - Hôpital Pasteur</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CLCC Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>I.C.O. Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss - ICANS - Institut de cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud - IUCT - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO Badalona - Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación de Investigación biomédica H. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación de Investigación Biomédica Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>August 1, 2023</last_update_submitted>
  <last_update_submitted_qc>August 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avelumab</keyword>
  <keyword>Cancer</keyword>
  <keyword>Anti PD-L1</keyword>
  <keyword>Therapeutic Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03260023
org study id: TG4001.12
nct id: NCT03260023
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The study will consist of two parts :

      In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 patients at
      increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will
      be no intra-patient dose escalation.

      In the phase II part 1, evaluation of efficacy and further evaluation of safety of the
      combination of TG4001 and avelumab will be performed in a single arm of patients with
      recurrent or metastatic HPV-16 positive advanced malignancies.

      In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will
      be performed in a randomized, open-label controlled study comparing TG4001 in combination
      with avelumab to avelumab alone in patients with HPV-16 positive advanced malignancies.

      In both phases, tumor response will be evaluated on local assessment using RECIST 1.1.

      All patients will be followed up until disease progression, death, or unacceptable toxicity,
      or study withdrawal for any reason, whichever occurs first.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Phase Ib: To evaluate the safety and tolerability of the combination of TG4001 plus avelumab in patients with recurrent or metastatic HPV-16 positive advanced malignancies
time frame: Day 28
description: Dose limiting toxicities (DLTs) includes the following:
Grade ≥ 3 drug related adverse event (AEs). However, fatigue, nausea/vomiting adequately treated with anti-emetics, endocrinopathies adequately controlled with one physiologic hormone replacement, skin toxicity and single laboratory values out of normal range without any clinical correlate, asymptomatic grade ≥3 lipase or amylase elevation, tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor or a transient Grade 3 infusion adverse event are excluded.
Liver function test abnormality:
AST or ALT > 5 x ULN
Total bilirubin > 3 x ULN
Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN
Drug related AE requiring treatment interruption for more than 2 weeks
measure: Phase II part 1: Overall Response Rate (ORR) by RECIST 1.1
time frame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
description: Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria over the the total number of evaluable patients.
measure: Phase II part 2: Progression Free Survival (PFS) by RECISIT 1.1
time frame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
description: Time from the date of randomization to death due to any cause, whichever occurs first.
measure: Overall Response Rate (ORR) by using RECIST 1.1 (phase Ib, phase II part 2)
time frame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
description: Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria over the the total number of evaluable patients
measure: Progression Free Survival (PFS) (phase Ib, Phase II part 1)
time frame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
description: Time from the date of first study treatment administration (Phase IB, Phase II Part1) to the date of first documented tumor progression or death due to any cause, whichever occurs first.
measure: Overall Survival (OS)
time frame: Every 3 months and up to 3 years
description: Time from the date of first study treatment administration (Phase Ib, Phase II part 1) or time from the date of randomization (Phase II part 2) to the date of death due to any cause.
measure: Duration of overall Response (DoR)
time frame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
description: Time from first documented response (CR or PR) until documented disease progression or death, whichever occurs first.
measure: Disease control rate (DCR)
time frame: Every 6 weeks for the first 9 months, then every 12 weeks up to 3 years
description: Proportion of patients whose best overall response is either CR, PR, or SD.
measure: Incidence of Adverse Event reported per CTCAE v4.03
time frame: up to 90 days after last study treatment administration
arm group label: TG4001/Avelumab
arm group type: Experimental
arm group label: Avelumab
arm group type: Experimental
description: Applicable for Phase II part 2.
intervention type: Biological
intervention name: TG4001
description: PhIb: Dose escalation PhII: Established RP2D for TG4001
arm group label: TG4001/Avelumab
intervention type: Drug
intervention name: Avelumab
description: Anti PD-L1
arm group label: Avelumab
arm group label: TG4001/Avelumab
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Transgene EU, Clinical Operations Department
phone: + 33 (0) 3 88 27 91 00
email: clinical.trials@transgene.fr
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
country: France
country: Spain
country: United States
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Carcinoma, Squamous Cell
mesh term: Avelumab